

Company Number 06884476

**YORK AGAINST CANCER**  
**A company limited by guarantee**  
**and**  
**A registered charity number 1130835**

**REPORT AND ACCOUNTS**

**For the year ended**  
**31 December 2020**

**HPH**  
**Chartered Accountants**  
**54 Bootham**  
**York**  
**YO30 7XZ**

# **YORK AGAINST CANCER**

## **CONTENTS**

|  | <b>Page</b>    |
|--|----------------|
| <b>Founders</b>                          | <b>1</b>       |
| <b>Chairman's Report</b>                 | <b>2</b>       |
| <b>Trustees' Report</b>                  | <b>3 - 15</b>  |
| <b>Auditor's Report</b>                  | <b>16 – 19</b> |
| <b>Statement of Financial Activities</b> | <b>20</b>      |
| <b>Balance Sheet</b>                     | <b>21</b>      |
| <b>Cash Flow Statement</b>               | <b>22</b>      |
| <b>Notes to the Financial Statements</b> | <b>23 - 33</b> |

## YORK AGAINST CANCER

### Founders

Prof Stephen Leveson

Mr John Craven

Prof Colin Garner

## **YORK AGAINST CANCER**

### **CHAIRMAN'S REPORT 2020**

I am sure I don't need to remind anybody about the impact Covid 19 has had during the year. It has had a significant effect on the day to day work that we all undertake, including the work of the Charity.

During the year our small and dedicated workforce led by General Manager Julie Russell remained to the fore in ensuring we delivered on our promise to support those in need, both individuals and families whenever circumstances allowed, and I am grateful for their dedication during what has been a very difficult time.

As you will be aware we have been forced to make a number of difficult decisions in the short term due to the on-going restrictions, but we look forward to the Charity being back and fully functioning in the not too distant future.

In the meantime, work continues, and while some events are on hold, the need to strategically plan for our future requirements goes on to ensure we remain in a position to continue the important services for people touched by cancer – services that will be even more important as we consolidate and expand on the outstanding work undertaken in the many areas that the Charity is involved in.

Our move to our new shop and offices at Vangarde Monks Cross did not take place as expected, and the continuing delay has been a source of frustration. The move is now planned in 2021 and will hopefully have happened by the time you read this. This will put the Charity far more central from an awareness point of view.

A number of Board member colleagues have retired this year, and we would like to record our thanks to Keith Hayton, Pat Kay, Gordon Topping and John Yeomans for the many years of hard work and dedication they have given. We also sadly lost a number of supporters and volunteers, and our thoughts go out to their families, and we wish them well for the future.

Every one of them supported the day to day work of the Charity, and our volunteers, our staff and all those who help in their own way enable us to continue to provide the important services and funding for research that the Charity is recognised for.

Despite the many restrictions, our minibus service was able to operate in difficult conditions at times, and our thanks go to Ian and Neil for providing this important service when many other cancer services were severely curtailed by the NHS. Working in the office, promoting the Charity or driving our minibus our small and important band of dedicated staff are the daily face of York Against Cancer, and ably supported by our committed army of volunteers, the Charity remains in good hands.

We have missed the regular involvement of our wonderful volunteers, but we know when things start to return to normal you will once again provide support in our shops and at numerous events throughout the year.

**Ian Yeowart**  
**Chair York Against Cancer**

## YORK AGAINST CANCER

### DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

The Directors (who are also the Trustees of the Charity and are listed below) are pleased to present their report of the Charitable Company for the year ended 31 December 2020.

#### Objectives and activities

The objects of the Charity are to raise funds to:

1. Foster and promote joint research between clinicians and research scientists in York and wider area and, by encouraging a more effective exchange of ideas and information, to advance the alleviation and cure of cancer.
2. Support treatment of cancer patients at York Hospital and the local area.
3. Fund education and information about cancer for patients and their families and the wider public.

The Trustees believe they have complied with the duty in section 4 of the 2006 Charities Act to have due regard to guidance published by the Charity Commission in respect of public benefit.

#### Aims and strategies

The Charity aims to provide support to cancer patients and the community through the: -

- funding of research programmes
- funding and the provision of services and resources for patients and their families
- funding of education initiatives

#### Achievements and performance

##### Research

##### *Jack Birch Unit (University of York)*

The Charity is committed to another 4 years supporting the work of the Jack Birch Unit. The roles supported by York Against Cancer are: -

Director of the Jack Birch Unit  
Laboratory technician

Assistant Director  
Administrative assistant

Research Fellow in Informatics at the Jack Birch Unit is also being supported from 2019 to 2024. A more in-depth report of the work of the Unit is detailed on pages 7 and 8.

#### Developments in the Year and Future Planning

The Board have continued their consistently adopted policy of only making commitments when the finance for these is already in place. The Board are mindful of the responsibility of ensuring that the generous donations received are used in the most effective manner possible to meet with the aims of the charity. With a sudden influx of a large legacy in 2016 the board established a Finance Sub-group to consider the most effective way to manage the funds for the future of the charity. The Board has agreed with the recommendations of the sub-group that a significant proportion of funds should be invested to provide for both future security of the charity and to ensure that the capital is used most effectively and to be available when future projects are considered and to ensure that the long-term plans and services the charity provides can be continued into the foreseeable future.

## **YORK AGAINST CANCER**

### **CHAIRMAN'S REPORT 2020**

I am sure I don't need to remind anybody about the impact Covid 19 has had during the year. It has had a significant effect on the day to day work that we all undertake, including the work of the Charity.

During the year our small and dedicated workforce led by General Manager Julie Russell remained to the fore in ensuring we delivered on our promise to support those in need, both individuals and families whenever circumstances allowed, and I am grateful for their dedication during what has been a very difficult time.

As you will be aware we have been forced to make a number of difficult decisions in the short term due to the on-going restrictions, but we look forward to the Charity being back and fully functioning in the not too distant future.

In the meantime, work continues, and while some events are on hold, the need to strategically plan for our future requirements goes on to ensure we remain in a position to continue the important services for people touched by cancer – services that will be even more important as we consolidate and expand on the outstanding work undertaken in the many areas that the Charity is involved in.

Our move to our new shop and offices at Vangarde Monks Cross did not take place as expected, and the continuing delay has been a source of frustration. The move is now planned in 2021 and will hopefully have happened by the time you read this. This will put the Charity far more central from an awareness point of view.

A number of Board member colleagues have retired this year, and we would like to record our thanks to Keith Hayton, Pat Kay, Gordon Topping and John Yeomans for the many years of hard work and dedication they have given. We also sadly lost a number of supporters and volunteers, and our thoughts go out to their families, and we wish them well for the future.

Every one of them supported the day to day work of the Charity, and our volunteers, our staff and all those who help in their own way enable us to continue to provide the important services and funding for research that the Charity is recognised for.

Despite the many restrictions, our minibus service was able to operate in difficult conditions at times, and our thanks go to Ian and Neil for providing this important service when many other cancer services were severely curtailed by the NHS. Working in the office, promoting the Charity or driving our minibus our small and important band of dedicated staff are the daily face of York Against Cancer, and ably supported by our committed army of volunteers, the Charity remains in good hands.

We have missed the regular involvement of our wonderful volunteers, but we know when things start to return to normal you will once again provide support in our shops and at numerous events throughout the year.

**Ian Yeowart**  
**Chair York Against Cancer**

## YORK AGAINST CANCER

### DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

The Directors (who are also the Trustees of the Charity and are listed below) are pleased to present their report of the Charitable Company for the year ended 31 December 2020.

#### Objectives and activities

The objects of the Charity are to raise funds to:

1. Foster and promote joint research between clinicians and research scientists in York and wider area and, by encouraging a more effective exchange of ideas and information, to advance the alleviation and cure of cancer.
2. Support treatment of cancer patients at York Hospital and the local area.
3. Fund education and information about cancer for patients and their families and the wider public.

The Trustees believe they have complied with the duty in section 4 of the 2006 Charities Act to have due regard to guidance published by the Charity Commission in respect of public benefit.

#### Aims and strategies

The Charity aims to provide support to cancer patients and the community through the: -

- funding of research programmes
- funding and the provision of services and resources for patients and their families
- funding of education initiatives

#### Achievements and performance

##### Research

##### *Jack Birch Unit (University of York)*

The Charity is committed to another 4 years supporting the work of the Jack Birch Unit. The roles supported by York Against Cancer are: -

Director of the Jack Birch Unit  
Laboratory technician

Assistant Director  
Administrative assistant

Research Fellow in Informatics at the Jack Birch Unit is also being supported from 2019 to 2024. A more in-depth report of the work of the Unit is detailed on pages 7 and 8.

#### Developments in the Year and Future Planning

The Board have continued their consistently adopted policy of only making commitments when the finance for these is already in place. The Board are mindful of the responsibility of ensuring that the generous donations received are used in the most effective manner possible to meet with the aims of the charity. With a sudden influx of a large legacy in 2016 the board established a Finance Sub-group to consider the most effective way to manage the funds for the future of the charity. The Board has agreed with the recommendations of the sub-group that a significant proportion of funds should be invested to provide for both future security of the charity and to ensure that the capital is used most effectively and to be available when future projects are considered and to ensure that the long-term plans and services the charity provides can be continued into the foreseeable future.

## **YORK AGAINST CANCER**

### **DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020**

The members of the Board are constantly looking at the needs of cancer patients and cancer services in the area to see where an investment could provide a significant improvement to the cancer services.

The delay in the Monks Cross development will mean that the charity will remain on the Huntington site for the present and the date for moving will be 2021.

The charity has continued to benefit from legacies during the year which give a great boost to the charity's funds, and we are immensely grateful to these generous people. Legacy income is, unpredictable and is another reason why the charity must husband its resources in the most effective way to enable the services we provide to both continue and develop.

#### **Mobile Chemotherapy Unit**

In recent years, the charity has worked on raising its profile, both locally and in a wider area of North and East Yorkshire with a successful rebranding exercise. With the Mobile Chemotherapy Unit project coming to fruition which takes chemotherapy services to the wider areas of the York Teaching Hospital, at Malton, Selby, Scarborough and Bridlington, it has enabled the charity to widen its reach. This has helped thousands of patients the time-consuming and tiring journeys to the hospital in York. In its first full year of operation the unit has been very well received by both medical staff and patients.

It also significantly increased the capacity of the hospital to provide the chemotherapy services to meet the needs of patients. Our fundraisers have been actively raising funds to help with the running costs of the enterprise.

#### **Respite Properties**

The holiday homes at Filey and Whitby continue to provide a welcome break, each in its own special environment. The many letters of appreciation we receive are an indication of how much a short break in these luxurious surroundings are appreciated. The YAC board is looking into extending this service through exploring opportunities to buy an additional property.

#### **Dermatoscope Project**

The dermatoscope project, launched 3 years previously, has continued to expand and develop and is really beginning to make an impact to help the early diagnosis of skin cancer, by which these specially designed photo units have been supplied to all GP practices in the area, has made the early diagnosis of skin cancer not only easier and more efficient but has greatly reduced the waiting time for patients to see a consultant. This model of this project has been picked up by other areas and is now being replicated in other hospitals

#### **Supporting patients**

The Health Care Assistant have continued to provide support for families affected by cancer. These appointments are made in conjunction with the NHS to provide support for patients and their families; support which is not available through the normal NHS services. This year complementary therapy arranged through the Cancer Care Centre has been significantly affected by Covid-19 and patients have been offered complementary therapy and other services virtually. Our minibus service has also been affected by Covid, for a few months it was not able to run but as soon as the restrictions allowed it resume, however, with a restricted number of passengers. It continues to be an excellent and much-valued service of transporting patients to St. James' Hospital.

## **YORK AGAINST CANCER**

### **DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020**

#### **Health Welfare Advisor**

The charity continues to support the Citizens Advice Bureau in their work with cancer patients at Scarborough hospital: this work provides support for those having cancer treatment and based at Scarborough to ensure that they receive all the help to which they are entitled.

#### **Management Report**

The small team of hardworking office staff deal effectively with all aspects of the day-to-day operation of the charity, and it is worth noting that during 2020 that there has been an inevitable impact on fundraising and charity/staff/board morale and the charity have striven to deal with those demands and risen to meet the challenges head on.

The teams work is sometimes challenging as they deal with people facing cancer and on occasions this can impact on their resolve, they deal with this together and their teamwork is impressive. The team are friendly and often are found smiling. The way it is possible for our manager and her staff to respond quickly to any requests or challenges is a key strength for York Against Cancer as a local charity.

#### **Minibus**

We continue to get very encouraging feedback from the users of the minibus, the Whitby apartment and the Filey holiday home. The members of staff have worked in close co-operation with the Cancer Care Centre and this has enabled the apartment to be used by some very deserving cases. The thoughtful and kind approach of our minibus drivers has also again been very much appreciated.

#### **The people supported by York Against Cancer**

Although the people directly employed by the charity are those listed above there are, in addition, those who are employed directly by others but whose salary costs are paid by York Against Cancer. All these posts are supported as the work done by these people directly enables the charity to achieve its goals. These posts are itemised below and illustrate the range of activities supported by the Board:

JBU - Director of the Jack Birch Unit

Assistant Director

Laboratory technician

Administrative assistant

Administrators at the Cancer Care Centre (3 staff covering 37 hours)

Health Care Assistant (part-time)

Complementary therapists (one full-time equivalent)

Clinical Research Nurse and Assistant posts at York Hospital (two-year funding to end of 2021)

Research Fellow in Informatics at the Jack Birch Unit (from 2019 to 2024)

All these supported positions are initially given for a fixed term (usually two or three years) and then reviewed by the Board. This is done to ensure that the money so generously raised by our supporters is used in the most efficient way.

## **YORK AGAINST CANCER**

### **DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020**

#### **Education**

The Cancer Awareness and Prevention group continues to work to spread information about cancer across as wide a range of the public as possible with an emphasis on young people. The work of the group is reported separately on page 9.

#### **Fundraising**

The retail outlets, at Huntington and the Hospital have continued to be an invaluable source of income and the hospital shop provides a very useful 'shop front' for the charity. The sterling work done by our volunteers; and our staff in the office has yet again given up many hours in the evening and at weekends to help raise funds and spread the message about York Against Cancer. The links with the local business community have again proved a great benefit to the charity. With all these efforts from our employed staff and volunteers the charity is able to provide more much-needed support to many in the local community. Compared to many charities, it is remarkable to consider that York Against Cancer does not employ a fundraiser as such and we are totally reliant on our supporters and volunteers for the funding we receive.

York Against Cancer is committed to maintaining high standards of fundraising and retail activity. The Charity is registered with the Fundraising Regulator. The Charity has recognised and begun to put in place a comprehensive policy for fundraising. The Charity does not use any third parties to act on its behalf in relation to fundraising. No complaints were received by the charity during 2019 in relation to its fundraising activities. For further information on fundraising activities undertaken during the year see page 10.

**DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020**

**Jack Birch Unit of Molecular Carcinogenesis  
Annual Report 2020**

What a year that was! I don't think there's anyone unaffected by the pandemic, but it's not all been bad news on the JBU front.

Back in January 2020 I attended the University of York Graduation Ceremony where York Against Cancer were conferred onto the College of Benefactors as a founding member. In late February, I visited India with a couple of University colleagues under the Global Challenges Research Fund programme to explore potential collaborations. Here we met many enthusiastic researchers with common interests in carcinogenesis mediated through contamination of water courses by heavy metals, such as cadmium. Then, just before lockdown, Simon Baker attended the Bladder Cancer Translational Meeting in Birmingham to present his work towards a new personalised therapy for Bladder Cancer.

Then came lockdown. Amazingly, Simon carried on lab work throughout the first lockdown as he had ongoing experimental work. This research resulted in a publication in a leading scientific journal and was featured on the front cover. The paper describes the "signatures" left by carcinogens and brings important new insight for understanding the causes of bladder cancer.

Although lockdown meant we could not travel, we were able to participate remotely by zoom in various scientific conferences, including the International Bladder Cancer Network in October (at which Simon presented). Our clinical fellow, Debora Morgante presented her research to the Biomaterials and Tissue Engineering Group meeting and won first prize. We also "Zoomed" into schools to spread the word about York Against Cancer, our research and the possibilities of scientific careers.

Of our staff and students. Jen returned from maternity leave in April; Edgar (Zhen Liu) returned to China to finish writing up his PhD and our York Against Cancer PhD student, Tom Crighton submitted his PhD thesis titled "Hippo and Sonic Hedgehog signalling pathway modulation of human urothelial tissue homeostasis". We were joined by Ryan Ellis as our latest York Against Cancer-funded student and by Ben Jarvis, a one-year Masters by Research student. Vlad Ungureanu also joined us as a PhD student based between the Departments of Electronic Engineering and Biology, and jointly supervised by Andrew Mason, among others. As our York Against Cancer-funded Independent Research Fellow, Andrew continues to develop the informatics capability of the JBU, including hiring Katie Skinner for one-year as a bioinformatician before she starts a PhD in cancer bioinformatics in the USA in Autumn 2021.

**DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020**

We missed running our cake stalls to raise funds for York Against Cancer but managed to raise £380 through the – you've guessed it – zoom quiz that Andrew Mason ran in November.



The JBU group carried on having weekly research meetings on zoom throughout the year.

As always, we are extremely grateful for research support from York Against Cancer, who help towards funding several salaries of staff in the Jack Birch Unit – plus the research fellowship of Dr Andrew Mason. Finally, I would like to acknowledge the invaluable contribution that our scientific and clinical collaborators make to the quality and output of our research.

**Professor Jenny Southgate, Director,  
Jack Birch Unit of Molecular Carcinogenesis, University of York**

**DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020**

**Cancer Education and Awareness Team**

**Annual Report 2020**

I became interim chair of the committee in January, following John Molyneux who has served for many years with the last 6 years as chair. John has been very enthusiastic and hardworking and was particularly supportive when I joined the committee. Last year also saw Steve Leveson and Keith Hayton stepping down. Both have been important members of our committee as well as key figures in the history of York Against Cancer.

I'm very pleased to report the activities of the committee for 2020 which, of course, were overshadowed by the Covid-19 Pandemic. The committee has met virtually, via Zoom, and many of our efforts have been adversely affected. With this in mind, I would like to outline our progress in 2020.

Following Simon Baker's hard work, the Enthuse partnership with local schools was due to start in early 2020. However, the Covid-19 pandemic struck and schools were forced to close. Throughout the year education has been severely disrupted and the project could not get underway. The funding provided will be rolled forward from the point that teachers are able to focus on the scheme.

Simon has also discussed with York University the possibility of making the Campus smoke free. Unfortunately, for logistical reasons, this could not be implemented. However, it was agreed to stop the sale of tobacco on Campus.

Because of school closures, we were unable to carry out our annual delivery of sun hats and sun awareness leaflets to primary schools. We will resume this important activity as soon as permitted.

Julie Russell and I continued our regular meetings [again virtual of course] with Dr. Dan Cottingham, the lead GP for cancer care at the CCG. It has been very helpful to share information regarding, for example, cancer screening programmes and the very encouraging success of the use of YAC funded dermato-scopes in Primary Care.

Again, unfortunately we were unable to hold our annual cancer awareness day in York city centre due to Covid-19 restrictions.

Lynn Bartram who sits on the committee is a Primary School Head. She highlighted the issue of providing support to children who are affected by cancer either through family or other contacts. Julie Russell and Lynn worked together to define a collection of age specific books which can be supplied to children requiring help. York Against Cancer will fund the supply of these books into schools.

In November the committee held a virtual brain-storming meeting to bring forward ideas which might form a development plan for 2021. Lively and interesting discussion resulted in suggestions that ranged from local and online media, through theatre workshops in schools to a medicinal herb garden. All projects to raise cancer awareness in our community.

Following a change of the York Against Cancer Terms of Reference in early 2020, I stood as interim chair of the committee through 2020. Lynn Bartram, who also sits on the main board, kindly agreed to become chair of the Education and Awareness committee in January 2021. I'm sure that her knowledge and experience in education will be invaluable in taking the work of the committee and York Against Cancer forward.

**Stuart Parker - Interim Chair**

**DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020**

**Fundraising report 2020**

As we started 2020, we could not have envisaged what we were facing regarding the pandemic, internationally, nationally, and locally. As the country went into lock down it meant that all our planned fundraising events were postponed. It was obvious quite early on that the charities fundraising income would be severely impacted by the situation but as a health related and caring charity our priority was to do everything to keep our fundraisers, supporters, volunteers, and staff safe.

Our regular fundraisers were contacted, new dates were discussed and diarised. This demonstrated that our faithful band of fundraisers were not going to let a pandemic stop them supporting us in the future. This is heart-warming and shows what our charity means to the people of York and the wider area of North and East Yorkshire.

Some fundraisers were determined to continue and either adapted their events to be Covid friendly or in fact changing their event to become a virtual event. It has made us and many of our fundraisers think about fundraising in a different way and in fact given it another dimension and virtual events are more than likely a thing of the future.

The situation has also given us the time to consider our fundraising methods; what we do, how we do them and in fact are there better, more efficient, and more profitable ways of fundraising.

Here are a few examples of how fundraising has continued during 2020

- Local band 'Sister madly' held a virtual concert on Facebook live raising £585
- The Jack Birch Unit held a zoom quiz which raised £380
- The York Peddlers set themselves a challenge to cycle 10,000 miles. They did by cycling individually and adding up their miles. They raised a huge £5,700

In conclusion, 2020 has been a difficult year for us but we are optimistic about the future and we look forward to working with our fundraisers and supporters long into the future.

Thank you to everyone who have fundraised and to those also who have plans to raise money for us we really do appreciate you all – thank you for your contributions.

**Julie Russell**  
**General Manager**

## YORK AGAINST CANCER

### DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

#### Structure, Governance and Management

The charity was incorporated on 22 April 2009 and its governing document is the memorandum and articles of association. The charity is a company limited by guarantee.

The charity is governed by a Board of Directors, supported by working groups as required. The Board members are all Trustees and include Officers of the Charity.

The Board meets four times a year and the various working groups meet as required during the year.

The members of the Board are volunteers. New Board members are elected by the existing members up to a maximum of twelve in total.

#### Trustee Induction and Training

New Trustees are briefed on their legal obligations under charity law, the committee and decision-making processes, the business plan and recent financial performance of the Charity. During their induction they meet key employees and other trustees. Trustees are encouraged to attend appropriate external training events where these will facilitate the undertaking of their role. At the end of each three tenure the trustees are required to update their trustee training.

#### Organisational Structure

The Board delegates the day-to-day management of the affairs of the Charity to one Board member, Keith Hayton, who serves as the Honorary Administrator (resigned 7 July 2020). This responsibility was taken on by Tarnia Hudson (commenced July 2020).

The members of staff employed by the Charity during the year were:

|                  |   |
|------------------|---|
| Julie Russell    | General Manager   |
| Heather Atkinson | Office & Accounts Manager   |
| Lauren Hudson    | Personal Assistant to General Manager from 9 <sup>th</sup> March 2020   |
| Nicola Doherty   | P.A. to General Manager until 7 <sup>th</sup> February 2020 – Office & Volunteer coordinator 10 <sup>th</sup> February 2020 |
| Helen Watkinson  | Retail Manager part-time until 7 <sup>th</sup> February 2020, full-time from 10 <sup>th</sup> February 2020                 |
| Francine Clee    | PR & Communications Officer (part-time)   |
| Ian Stephenson   | Minibus Driver (part-time)  |
| Neil Johnson     | Minibus Driver (part-time)  |

#### Board membership

In March 2013 the Board adopted, by unanimous agreement, a protocol to introduce a three-year rule from that date. Board members continue to actively seek new trustees, taking into consideration a good mix of professional skills including business, education and medical. A term of office for a director is 3 years, after which time he/she may be re-elected for a further 3-year term up to a maximum of 9 years in total (details of current terms of office available on request).

#### Remuneration of key personnel

All members of staff employed by the charity have an annual appraisal in January following which salaries are set for the following 12 months. The appraisals are carried out by the General Manager.

No Board member received any income or expenses for their work for the charity.

## **YORK AGAINST CANCER**

### **DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020**

#### **Related parties**

The Charity owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited, a company registered in England and Wales. The subsidiary is used for the raising of funds for the Charity through the sale of bought in goods through the Charity's two shops.

#### **Risk management**

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the Charity and continues to take measures to reduce those risks to an acceptable minimum. The policy of only making new commitments when the funds are in hand is a very practical way of eliminating unnecessary financial risks. By its very nature a charity relies on fundraising, donations and legacies which can vary a great deal. Ongoing commitments are to our staff, to a range of time limited research and care projects and to the leasehold of the new premises at the LNER community stadium with a delayed move in 2021. The move will provide greater storage and office space and a retail outlet with a good footfall. The trustees have calculated the move is necessary for the further development of the work of the charity. It should be emphasised that supporting staff not directly employed by York Against Cancer is always done on a time-limited basis (typically two years) which is renewed as appropriate provided funds are available.

The Board is very mindful that the charity has a substantial reserve of funds and seeks to find effective ways in which these can be utilised to fulfil the aims of York Against Cancer, whilst at the same time investing some funds to provide for future security.

#### **Financial review and policies**

The Charity's funds in 2020 increased by £24,290. Large investment gains have reduced the deficit significantly. Prior to any adjustment for investments, the Charity made a deficit of £146,787 (2019 deficit of £498,309). The charity was expecting a deficit as it utilises some of the excess free reserves for charitable purposes.

The principal funding sources are fund-raising, the trading shops, donations, legacies and members' subscriptions. Gross income in 2020 amounted to £389,859 (2019 £1,708,583). These funds support the key objectives of the Charity, namely, to fund clinical research, to support people with cancer and to fund education about the disease.

£163,187 was committed on project expenditure, to support the Charity's ongoing projects. Due to COVID-19 there were limited additional projects taken on this year. The detail of funding of projects can be found in note 6.

#### **Investment powers and policy**

The Trustees have a general power of investment and so have the discretion to invest in such investment assets as they see fit. The Trustees have set a policy that sufficient of the 'free reserves' should be invested to retain a reasonable liquidity to meet grant commitments.

Our policy is a medium low risk approach for the growth of the portfolio of investments. The investment managers have discretion about how the investments are managed within the policy parameters set by the Trustees.

**DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020**

The Investment Group oversees the investment management of the Charity's funds. The services of HSBC Private Bank and Ruffer were retained as investment managers during 2020. Funds not invested are held on deposit to earn interest.

The total return on the investment portfolio managed by HSBC for the year ended 31 December 2020, before fees, was 0.43% (2019 14.67%). The total return on investment portfolio managed by Ruffer for the year ended 31 December 2020, before fees, was 11.8% (2019 6.8%).

**Reserves Policy**

The reserves policy is to generate a stable and sustainable return to fund grant making, to ensure continued financial security and to provide for contingencies. Cash reserves are accumulated before making a binding commitment to fund a project due to the nature and uncertainty of the income streams. The total funds held as at 31 December 2020 are £4,282,644 (2019 £4,258,354).

The Board is very mindful that the charity has a substantial reserve of funds at present after the receipt of some large legacies. The board is actively seeking to find effective ways in which these can be utilized to fulfil the aims of York Against Cancer, whilst at the same time investing some funds to provide for future security.

**Undesignated Fund**

These are free reserves retained to provide working capital and funds for future projects. At the end of the financial year, the free reserves were £3,503,531 (2019 £3,434,524) accumulated largely due to the receipt of several generous legacies, which by their very nature are unpredictable. The level of free reserves will enable the Charity to give significant support to worthwhile projects which make a measurable impact.

**Designated Funds**

Designated funds are part of the unrestricted funds which trustees have earmarked for assets held for the use in the charity and specific projects. At the year end, The Charity had consolidated designated funds of £635,088 (2019 £667,862) details of which are given in Note 16 of the financial statements.

**Restricted Funds**

Restricted funds represent monies raised by the Charity from public appeals for specific projects. At the year end, the Charity had restricted funds of £144,025 (2019 £155,968) details of which are given in Note 17 to the financial statements.

COVID-19 has had a significant impact on donations and fundraising since April 2020 as events have been either cancelled or postponed. The charity has significant reserves brought forward and these will be used to help support the charity adapt where needed and keep its on-going commitments.

**DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020**

**Directors and Trustees Responsibilities**

The purpose of this statement is to distinguish the Directors' and Trustees' responsibilities for the financial statements from those of the auditors as stated in their report.

Company and charity law require the Directors and Trustees to prepare financial statements which give a true and fair view of the Charitable Company's state of affairs at the end of its financial activities for that year. In preparing those financial statements the Trustees are required to:

- Select suitable accounting policies and then apply them consistently
- Make judgements and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going concern basis unless it is inappropriate to assume that the Charitable Company will continue in operation.

The Directors and Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Charitable Company and enables them to ensure that the financial statements comply with the Companies Act 2006 and applicable charity law. They are also responsible for safeguarding the assets of the Charitable Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Directors and Trustees are aware:

- There is no relevant information of which the Charitable Company's auditor is unaware; and
- The Directors and Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

Approved by the Board on 14 September 2021 and signed on its behalf by:

Ian Yeowart  
*Director and Trustee*

## YORK AGAINST CANCER

### DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

#### Reference and administrative details

|                                      |   |   |  |
|--------------------------------------|---|---|--|
| Registered Charity                   | number 1130835  | Company Limited<br>by Guarantee   | number 06884476  |
| Principal Office and Trading Address |   |   | 31 - 33 North Moor Road<br>Huntington<br>York<br>YO32 9QN  |
| Company Secretary                    | Julie Pamela Russell  |   |  |
| Directors and<br>Trustees            | Andrew Proctor<br>Angela Darby<br>Rachel Goddard<br>Michael John Stower<br>William Mark Sessions<br>Ian Yeowart<br>Sarah Wearing<br>Tarnia Hudson<br>Prof Stephen Leveson<br>Michael Patrick Shepherd | Dr Lynn Bartram (appointed September 2020)<br>Michael Sweet (appointed September 2020)<br>Robert Onyett (appointed September 2020)<br>John Francis Yeomans (resigned 7 July 2020)<br>Edward Keith Hayton (resigned 7 July 2020)<br>Patricia Anne Kay (resigned 7 July 2020)<br>Gordon Andrew Topping (resigned February 2020) |  |
|                                      | Trustee's protocol / length of service document available on request  |   |  |
| Accountants                          | HPH<br>Chartered Accountants<br>54 Bootham<br>York<br>YO30 7XZ  | Auditors  | Townends Accountants LLP<br>Chartered Accountants<br>Fulford Lodge<br>1 Heslington Lane<br>Fulford<br>York<br>YO10 4HW |
| Bankers                              | National Westminster Bank<br>1 Market Street<br>York<br>YO1 8SR   | Solicitors  | Harrowells<br>Moorgate House<br>Clifton Moorgate<br>York<br>YO30 4WY   |
| Investment Advisors                  | HSBC Global Asset<br>Management<br>78 St James's Street<br>London<br>SW1A 1EJ   |   | Ruffer LLP<br>80 Victoria Street<br>London<br>SW1E 5JL   |

# **YORK AGAINST CANCER**

## **COMPANY LIMITED BY GUARANTEE**

### **INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER**

**YEAR ENDED 31 DECEMBER 2020**

#### **Opinion on financial statements**

We have audited the financial statements of York Against Cancer for the year ended 31 December 2020, which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement, the Income and Expenditure Account and related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards including Financial Reporting Standard FRS102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 December 2020 and of its incoming resources and application of resources for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with requirements of the Companies Act 2006.

#### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the trustee's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the original financial statements were authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

#### **Other information**

The trustees are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

# **YORK AGAINST CANCER**

## **COMPANY LIMITED BY GUARANTEE**

### **INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER**

**YEAR ENDED 31 DECEMBER 2020**

#### **Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report (incorporating the strategic report and the directors' report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' report (incorporating the strategic report and the directors' report) have been prepared in accordance with applicable legal requirements.

#### **Matter on which we are required to report by exception**

In the light of the knowledge and understanding of the Charity and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Annual Report.

We have nothing to report in respect of the following matters where the Companies Act 2006 required us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Board of Trustees's remuneration specified by law are not made; or
- we have not obtained all the information and explanations necessary for the purposes of our audit.

#### **Responsibilities of the trustees**

As explained more fully in the trustees' responsibilities statement set out on page 14, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the Charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the Charity or to cease operations, or have no realistic alternative but to do so.

#### **Our responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

## **YORK AGAINST CANCER**

### **COMPANY LIMITED BY GUARANTEE**

#### **INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER**

**YEAR ENDED 31 DECEMBER 2020**

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- We have obtained an understanding of the legal and regulatory framework applicable to the Charity through discussions with senior management and review of the regulatory framework of any professional or membership bodies that the Charity is a part of. The Charity uses third parties to ensure that it remains up to date with changes and to review compliance with all its legal and regulatory requirements. In making our assessment of detecting irregularities, including fraud, we have discussed the issue with management who have advised that, other than changes to the work place to ensure that they are Covid-19 compliant, there have been no changes and the Charity remains compliant with its legal and regulatory requirement. Nothing has been brought to light in completing our audit work that contradicts this.
- The following laws and regulations have been identified as being of significance in the context of the Charity; Companies Act 2006, Charities Act 2011, fundraising regulations, health and safety legislation, employment laws, data protection, and relevant tax laws.
- In making our assessment of the susceptibility of the Charity's financial statements to material misstatement, we have also considered how fraud might occur. No instances of material misstatement or fraud have been noted in the audit of the accounts for the year ended 31 December 2020.
- All matters regarding non-compliance with laws and regulations and fraud have been communicated to all members of the audit engagement team. The engagement partner has assessed that the engagement team has the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations, affected by the inherent difficulty in detecting irregularities, the effectiveness of the Charity's controls, and the nature, timing and extent of the audit procedures performed.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.

**YORK AGAINST CANCER**

**COMPANY LIMITED BY GUARANTEE**

**INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER**

**YEAR ENDED 31 DECEMBER 2020**

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the director.
- Conclude on the appropriateness of the director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Charity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Charity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

**Use of our report**

This report is made solely to the Charity's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Charity's members those matters we are required to state to them in an auditors report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charity's members as a body, for our audit work, for this report, or for the opinions we have formed.

.....  
**Paul Sharpe FCA (Senior Statutory Auditor)**

**For and on behalf of  
Townends Accountants LLP  
Chartered Accountants & Statutory Auditor**

**Date: 14 September 2021**

Carlisle Street  
Goole  
East Riding of Yorkshire  
DN14 5DX

**YORK AGAINST CANCER**  
**CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES**  
**AND INCOME AND EXPENDITURE ACCOUNT**  
**FOR THE YEAR ENDED 31 DECEMBER 2020**

|   | Note | Unrestricted<br>General<br>Fund<br>£ | Designated<br>Funds<br>£ | Restricted<br>Funds<br>£ | Year ended<br>31 Dec<br>2020<br>£ | Year ended<br>31 Dec<br>2019<br>£ |
|---|------|--------------------------------------|--------------------------|--------------------------|-----------------------------------|-----------------------------------|
| <b>Income and endowments from:</b>                  |      |                                      |                          |                          |                                   |                                   |
| Donations and legacies                              | 2    | 182,105                              | -                        | 600                      | 182,705                           | 1,365,532                         |
| Other trading activities                            | 3    | 157,863                              | -                        | -                        | 157,863                           | 274,018                           |
| Investments   | 4    | 49,291                               | -                        | -                        | 49,291                            | 69,033                            |
| <b>Total</b>  |      | <b>389,259</b>                       | <b>-</b>                 | <b>600</b>               | <b>389,859</b>                    | <b>1,708,583</b>                  |
| <b>Expenditure on:</b>                              |      |                                      |                          |                          |                                   |                                   |
| Raising funds                                       | 5    | 156,656                              | -                        | -                        | 156,656                           | 186,092                           |
| Charitable activities                               | 6    | 286,513                              | 80,934                   | 12,543                   | 379,990                           | 2,020,800                         |
| <b>Total</b>  |      | <b>443,169</b>                       | <b>80,934</b>            | <b>12,543</b>            | <b>536,646</b>                    | <b>2,206,892</b>                  |
| <b>Net expenditure before losses on investments</b> |      | <b>(53,910)</b>                      | <b>(80,934)</b>          | <b>(11,943)</b>          | <b>(146,787)</b>                  | <b>(498,309)</b>                  |
| Net gains on investments                            | 11   | 171,077                              | -                        | -                        | 171,077                           | 351,402                           |
| <b>Net income/(expenditure)</b>                     |      | <b>117,167</b>                       | <b>(80,934)</b>          | <b>(11,943)</b>          | <b>24,290</b>                     | <b>(146,907)</b>                  |
| <b>Transfers between funds</b>                      | 16   | <b>(48,160)</b>                      | <b>48,160</b>            | <b>-</b>                 | <b>-</b>                          | <b>-</b>                          |
| <b>Net movement in funds</b>                        |      | <b>69,007</b>                        | <b>(32,774)</b>          | <b>(11,943)</b>          | <b>24,290</b>                     | <b>(146,907)</b>                  |
| <b>Reconciliation of funds:</b>                     |      |                                      |                          |                          |                                   |                                   |
| Total funds brought forward                         |      | 3,434,524                            | 667,862                  | 155,968                  | 4,258,354                         | 4,405,261                         |
| <b>Total funds carried forward</b>                  |      | <b>£ 3,503,531</b>                   | <b>£ 635,088</b>         | <b>£ 144,025</b>         | <b>£ 4,282,644</b>                | <b>£ 4,258,354</b>                |

*The notes on pages 23 to 33 form part of these financial statements.*

**YORK AGAINST CANCER**  
(Registration number: 06884476)

**BALANCE SHEET**  
**AS AT 31 DECEMBER 2020**

|   | Note  | Charity<br>2020<br>£ | Consolidated<br>2020<br>£ | Charity<br>2019<br>£ | Consolidated<br>2019<br>£ |
|---|-------|----------------------|---------------------------|----------------------|---------------------------|
| <b>FIXED ASSETS</b>                                   |       |                      |                           |                      |                           |
| Tangible Fixed Assets                                 | 12    | 573,526              | 585,342                   | 589,541              | 600,882                   |
| Investments   | 11    | 3,741,011            | 3,741,010                 | 3,548,077            | 3,548,076                 |
|   |       | 4,314,537            | 4,326,352                 | 4,137,618            | 4,148,958                 |
| <b>CURRENT ASSETS</b>                                 |       |                      |                           |                      |                           |
| Stock   |       | -                    | 55,295                    | -                    | 57,259                    |
| Debtors   | 13    | 551,936              | 462,285                   | 783,450              | 694,330                   |
| Cash at Bank and in Hand                              |       | 827,681              | 898,835                   | 1,168,245            | 1,237,711                 |
|   |       | 1,379,617            | 1,416,415                 | 1,951,695            | 1,989,300                 |
| <b>CREDITORS: amounts falling due within one year</b> | 14    | 487,559              | 499,107                   | 615,171              | 627,626                   |
| <b>NET CURRENT ASSETS</b>                             |       | 892,058              | 917,308                   | 1,336,524            | 1,361,674                 |
| <b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>          |       | 5,206,595            | 5,243,660                 | 5,474,142            | 5,510,632                 |
| <b>CREDITORS: amounts falling due after one year</b>  | 15    | 961,016              | 961,016                   | 1,252,278            | 1,252,278                 |
| <b>NET ASSETS</b>                                     |       | £ 4,245,579          | £ 4,282,644               | £ 4,221,864          | £ 4,258,354               |
| <b>THE FUNDS OF THE CHARITY</b>                       |       |                      |                           |                      |                           |
| <b>Unrestricted</b>                                   |       |                      |                           |                      |                           |
| Undesignated  | 18    | 3,478,282            | 3,503,531                 | 3,409,375            | 3,434,524                 |
| Designated  | 16,18 | 623,272              | 635,088                   | 656,521              | 667,862                   |
| <b>Restricted</b>                                     | 17,18 | 144,025              | 144,025                   | 155,968              | 155,968                   |
| <b>TOTAL CHARITY FUNDS</b>                            |       | £ 4,245,579          | £ 4,282,644               | £ 4,221,864          | £ 4,258,354               |

Approved by the Trustees on 14 September 2021 and signed on its behalf by:

S B Wearing  
Director and Trustee

The notes on pages 23 to 33 form part of these financial statements.

**YORK AGAINST CANCER  
CONSOLIDATED CASHFLOW STATEMENT  
FOR THE YEAR ENDED 31 DECEMBER 2020**

|   | Note      | 2020<br>£        | 2019<br>£          |
|---|-----------|------------------|--------------------|
| <b>Cash flows from operating activities:</b>                              |           |                  |                    |
| <b>Net cash provided by/(used in) operating activities</b>                | <b>21</b> | (363,320)        | 6,206              |
| <b>Cash flows from investing activities:</b>                              |           |                  |                    |
| Dividends, interest and rents from investments                            |           | 49,291           | 69,033             |
| Purchase of property, plant and equipment                                 |           | (2,990)          | (9,926)            |
| Proceeds from sales of investments  |           | 1,095,488        | 1,295,325          |
| Purchase of investments   |           | (1,117,345)      | (825,288)          |
| <b>Net cash provided by/(used in) investing activities</b>                |           | <u>24,444</u>    | <u>529,144</u>     |
| <b>Change in cash and cash equivalents in the reporting period</b>        |           | (338,876)        | 535,350            |
| <b>Cash and cash equivalents at the beginning of the reporting period</b> |           | <u>1,237,711</u> | <u>702,361</u>     |
| <b>Cash and cash equivalents at the end of the reporting period</b>       |           | <u>£ 898,835</u> | <u>£ 1,237,711</u> |

*The notes on pages 23 to 33 form part of these financial statements.*

## YORK AGAINST CANCER

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

#### 1. ACCOUNTING POLICIES

##### **Legal entity**

York Against Cancer is regulated by the Charities Commission (1130835), limited by guarantee and is registered in England and Wales. The address of the registered office and principal place of business is 31 - 33 North Moor Road, Huntington, York, YO32 9QN.

##### **Basis of preparation**

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The consolidated accounts include the results of the Charitable Company and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

No separate SOFA has been presented for the Charitable Company alone as permitted by the SORP.

The Charitable Company constitutes a public benefit entity as defined by FRS 102.

The accounts are presented in UK Sterling pounds (£).

##### **Going Concern**

The Charitable Company has cash resources and has no requirement for external funding. The cash and investments held are sufficient to see the Charitable Company through the financial impact of COVID-19. The Directors and Trustees have a reasonable expectation that the Charitable Company has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting appropriate in preparing the annual financial statements.

##### **Income**

###### Donations and legacies

Credit is taken for donations and subscriptions when they are received. Credit is taken for legacies when received or if, before receipt, there is sufficient evidence to provide the necessary certainty that the legacy will be received and the value of the incoming resources can be measured with sufficient reliability.

###### Other trading activities

Fundraising income - represents gross income from events.

Subsidiary's non-charitable trading turnover - represents gross income from York Against Cancer Trading Company Limited, the Charitable Company's trading subsidiary.

###### Investments

Investment income has been accounted for on an accruals basis.

##### **Expenditure**

###### Raising funds

Fundraising costs - represents the total costs of fundraising events and activities held during the year.

Non charitable trading expenditure - comprises of the direct costs and administrative costs of the Charitable Company's trading subsidiary, York Against Cancer Trading Company Limited.

###### Charitable activities

Direct costs - comprises of expenditure on various projects the Charitable Company is supporting and is accounted for in full when the Charitable Company commits to provide the funding.

Support costs - comprises of the salaries and office expenses of the Charitable Company.

Governance costs - comprises the costs associated directly with the management by the Directors/Trustees of the Charitable Company's activities, including audit fees and costs of meetings.

All costs are apportioned on an actual cost basis.

## YORK AGAINST CANCER

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

#### 1. ACCOUNTING POLICIES (continued)

##### Pension costs

The Charitable Company operates a defined contribution money purchase pension scheme for specific employees. The assets of the scheme are invested and managed independently of the finances of the Charitable Company. The charge for pension costs represents the contributions payable in the year.

##### Fixed Assets

Individual fixed assets costing £200 or more are capitalised and included in the accounts at cost.

Tangible fixed assets are depreciated over their expected useful lives at the following annual rates:

|                             |                                |
|-----------------------------|--------------------------------|
| Freehold/Leasehold property | at straight line over 50 years |
| Equipment                   |                                |
| - Shop and office equipment | at straight line over 10 years |
| - Computer equipment        | at straight line over 3 years  |
| - Respite home equipment    | at straight line over 4 years  |
| Motor vehicles              | at 25% reducing balance        |

##### Stock

Stock is valued at the lower of cost and net realisable value. Cost is computed on a first in first out basis. Net realisable value is based on estimated selling price less the estimated cost of disposal.

##### Funds Structure

Unrestricted Funds are funds which are available for use or retention at the discretion of the Directors/Trustees, in accordance with the Charity's objects. Designated Funds represent unrestricted funds earmarked by the Directors/Trustees for particular purposes. Restricted Funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal. Details of Designated and Restricted Funds are contained in Notes 16 and 17, respectively.

##### Investments

The investment portfolios have been valued at market value at 31 December 2020. The SOFA includes the net gains and losses on investments arising on revaluation at the year end and on disposals throughout the year. Realised gains and losses on sales of investments are calculated as the difference between the sale proceeds and opening market value. Unrealised gains and losses represent the movement between market values.

##### Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

##### Cash at bank and in hand

Cash at bank and cash in hand includes cash and any short term deposit accounts with a maturity of three months or less from the date of opening.

##### Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

##### Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

##### Operating Leases

Rentals paid under operating leases are charged in the SOFA on a straight line basis over the lease term.

# YORK AGAINST CANCER

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

| 2. DONATIONS AND LEGACIES | Unrestricted<br>£ | Restricted<br>£ | 2020<br>£ | 2019<br>£   |
|---------------------------|-------------------|-----------------|-----------|-------------|
| Donations                 | 117,589           | 600             | 118,189   | 155,183     |
| In Memoriam               | 24,957            | -               | 24,957    | 32,312      |
| Legacies                  | 13,225            | -               | 13,225    | 1,168,941   |
| Government grant          | 21,334            | -               | 21,334    | -           |
| Intangible income         | 5,000             | -               | 5,000     | 9,096       |
|                           | £ 182,105         | £ 600           | £ 182,705 | £ 1,365,532 |

Intangible income comprises accounting services, a proportion of which is provided free of charge for the preparation of the Charitable Company and Subsidiary statutory accounts. A corresponding amount is included within governance costs.

| 3. OTHER TRADING ACTIVITIES                  | 2020<br>£ | 2019<br>£ |
|--|-----------|-----------|
| Fundraising income                           | 72,639    | 150,469   |
| Subsidiary's non-charitable trading turnover | 85,224    | 123,483   |
| Miscellaneous income                         | -         | 66        |
|  | £ 157,863 | £ 274,018 |

| 4. INVESTMENTS     | 2020<br>£ | 2019<br>£ |
|--------------------|-----------|-----------|
| Interest received  | 2,696     | 3,463     |
| Dividends received | 46,595    | 65,570    |
|                    | £ 49,291  | £ 69,033  |

| 5. ANALYSIS OF RAISING FUNDS       | Unrestricted<br>£ | Restricted<br>£ | 2020<br>£ | 2019<br>£ |
|------------------------------------|-------------------|-----------------|-----------|-----------|
| Advertising                        | 7,900             | -               | 7,900     | 13,181    |
| Fundraising costs                  | 65,847            | -               | 65,847    | 77,106    |
| Non charitable trading expenditure | 70,995            | -               | 70,995    | 81,865    |
| Investment fees                    | 11,914            | -               | 11,914    | 13,940    |
|                                    | £ 156,656         | £ -             | £ 156,656 | £ 186,092 |

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2020

6. ANALYSIS OF CHARITABLE ACTIVITIES

| <i>Direct project costs:</i>     | Unrestricted<br>£ | Restricted<br>£ | 2020<br>£ | 2019<br>£   |
|----------------------------------|-------------------|-----------------|-----------|-------------|
| <b>Research</b>                  |                   |                 |           |             |
| Jack Birch Unit                  | -                 | -               | -         | 1,413,264   |
| Clinical Trial Nurses            | 19,239            | -               | 19,239    | 127,478     |
| <b>Support and Care</b>          |                   |                 |           |             |
| Cancer Care Centre               | 26,330            | -               | 26,330    | 47,803      |
| Complementary therapy            | 29,541            | -               | 29,541    | 44,003      |
| Health Care Assistant            | 7,865             | -               | 7,865     | 13,052      |
| Respite property expenses        | 29,257            | -               | 29,257    | 41,315      |
| Minibus running costs            | 25,562            | -               | 25,562    | 21,122      |
| Mobile Chemotherapy Unit         | -                 | 321             | 321       | -           |
| Psychology services              | 5,680             | -               | 5,680     | -           |
| Restricted grants                | -                 | 12,222          | 12,222    | -           |
| Family Support Worker            | -                 | -               | -         | 22,379      |
| Health Welfare Advisor           | -                 | -               | -         | 95,000      |
| Hospital equipment               | -                 | -               | -         | 35,473      |
| Release of committed projects    | -                 | -               | -         | (96,508)    |
| <b>Education</b>                 |                   |                 |           |             |
| Education expenses               | 7,170             | -               | 7,170     | 26,353      |
|                                  | 150,644           | 12,543          | 163,187   | 1,790,734   |
| <b>Support costs:</b>            |                   |                 |           |             |
| Staff costs                      | 157,081           | -               | 157,081   | 156,400     |
| Staff training and travel        | 1,702             | -               | 1,702     | 3,597       |
| Rent and rates                   | 4,352             | -               | 4,352     | 12,773      |
| Heat and light                   | 1,666             | -               | 1,666     | 1,668       |
| Repairs and maintenance          | 1,932             | -               | 1,932     | 1,073       |
| Insurances                       | 2,963             | -               | 2,963     | 3,374       |
| Printing, stationery and postage | 4,856             | -               | 4,856     | 3,943       |
| Computer expenses                | 7,867             | -               | 7,867     | 8,425       |
| Telephone                        | 1,710             | -               | 1,710     | 1,514       |
| Sundry expenses                  | 3,953             | -               | 3,953     | 4,407       |
| Depreciation                     | 16,015            | -               | 16,015    | 16,632      |
|                                  | 204,097           | -               | 204,097   | 213,806     |
| <b>Governance costs:</b>         |                   |                 |           |             |
| Audit fees                       | 3,480             | -               | 3,480     | 3,480       |
| Accountancy fees                 | 7,663             | -               | 7,663     | 11,596      |
| Bank charges                     | 1,563             | -               | 1,563     | 1,184       |
|                                  | 12,706            | -               | 12,706    | 16,260      |
| Total charitable activities      | £ 367,447         | £ 12,543        | £ 379,990 | £ 2,020,800 |

# YORK AGAINST CANCER

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

### 7. NET INCOMING RESOURCES FOR THE YEAR

|   | 2020<br>£ | 2019<br>£ |
|---|-----------|-----------|
| This is stated after charging:            |           |           |
| Depreciation                              | 18,530    | 18,849    |
| Auditor's remuneration for audit services | 3,480     | 3,480     |

### 8. REMUNERATION AND EXPENSES OF TRUSTEES

None of the Trustees received any remuneration or benefits by virtue of being a trustee of the Charity and no Trustees were reimbursed any expenses incurred for services provided to the Charity.

### 9. STAFF COSTS

|                       | 2020<br>£        | 2019<br>£        |
|-----------------------|------------------|------------------|
| Wages and salaries    | 155,368          | 137,566          |
| Social security costs | 8,710            | 8,181            |
| Pension costs         | 7,104            | 6,143            |
| Medical Insurance     | 4,432            | 4,510            |
|                       | <u>£ 175,614</u> | <u>£ 156,400</u> |

The average monthly head count was 8 staff (2019 8) and the average monthly number of full-time equivalent employees (including casual and part-time staff) during the year were as follows:

|   |   |   |
|---|---|---|
| Management and administration of the Charitable Company | 7 | 7 |
|---|---|---|

No employee received emoluments in excess of £60,000.

The key management personnel of the Charitable Company, comprise the directors and trustees and the General Manager. The total employee benefits of the key management personnel of the Charitable Company were £49,937 (2019 - £49,196).

### 10. SUBSIDIARY COMPANY

The Charitable Company owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited. This company is registered in England and Wales (reg. no. 3405708) and its registered office is 31 North Moor Road, Huntington, York, YO32 9QN. The subsidiary is used for the raising of funds for the Charitable Company through the sale of bought in goods through the Charitable Company's shop and stalls. All activities have been consolidated on a line by line basis in the SOFA.

There is a loan account between the Charitable Company and the subsidiary. The balance on the loan account outstanding at the year end was £95,637 (2019 £93,645). Interest of £141 (2019 £1,355) was charged during the year in respect of this loan.

A summary of the results of the subsidiary is shown below:

|   | 2020<br>£       | 2019<br>£       |
|---|-----------------|-----------------|
| Turnover                                      | 85,224          | 123,483         |
| Cost of sales                                 | <u>(46,891)</u> | <u>(53,112)</u> |
| Gross profit                                  | 38,333          | 70,371          |
| Administrative expenses                       | <u>(48,953)</u> | <u>(62,391)</u> |
| Operating profit                              | (10,620)        | 7,980           |
| Other operating income                        | 11,334          | -               |
| Interest payable                              | <u>(141)</u>    | <u>(1,355)</u>  |
| Profit on ordinary activities before taxation | 573             | 6,625           |
| Taxation                                      | <u>-</u>        | <u>-</u>        |
| Profit on ordinary activities after taxation  | 573             | 6,625           |
| Amount gifted to York Against Cancer          | <u>-</u>        | <u>-</u>        |
| Retained within/(withdrawn from) Subsidiary   | <u>£ 573</u>    | <u>£ 6,625</u>  |
| Net Assets                                    | <u>£ 37,063</u> | <u>£ 36,490</u> |

# YORK AGAINST CANCER

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

### 11. INVESTMENTS

| <b>Consolidated</b>                                      | <b>2020</b>        | <b>2019</b>        |
|--|--------------------|--------------------|
|  | <b>£</b>           | <b>£</b>           |
| Market value at 1 January 2020                           | 3,548,076          | 3,666,711          |
| Additions at cost  | 1,117,345          | 825,288            |
| Disposals  | (1,095,488)        | (1,295,325)        |
| Revaluations   | 171,077            | 351,402            |
|  |                    |                    |
| Market value at 31 December 2020                         | <u>£ 3,741,010</u> | <u>£ 3,548,076</u> |
|  |                    |                    |
| Analysis of investments by class:                        |                    |                    |
| Listed investments                                       | <u>£ 3,741,010</u> | <u>£ 3,548,076</u> |
|  |                    |                    |
| The historical cost of the above investments amounts to: | <u>£ 3,521,243</u> | <u>£ 3,521,243</u> |

The following material investments are over 5% by value of the investments held

|                                     | <b>2020</b>         | <b>2019</b>         |
|-------------------------------------|---------------------|---------------------|
|                                     | <b>Market value</b> | <b>Market value</b> |
|                                     | <b>£</b>            | <b>£</b>            |
| HSBC FTSE All Share Index           | 302,095             | 278,825             |
| Ruffer Charity Assets Trust Account | 2,010,192           | 1,798,655           |
|                                     |                     |                     |
|                                     | <u>£ 2,312,287</u>  | <u>£ 2,077,480</u>  |

The Charitable Company holds all of the issued shares of its subsidiary undertaking York Against Cancer Trading Company Limited, at cost of £1, in addition to the above investments.

### 12. TANGIBLE FIXED ASSETS

|                       | <b>Property</b>  | <b>Motor</b>    | <b>Equipment</b> | <b>Charity</b>   | <b>Subsidiary -</b> | <b>Consolidated</b> |
|-----------------------|------------------|-----------------|------------------|------------------|---------------------|---------------------|
|                       | <b>£</b>         | <b>Vehicles</b> | <b>£</b>         | <b>Total</b>     | <b>Shop</b>         | <b>Total</b>        |
|                       |                  | <b>£</b>        |                  | <b>£</b>         | <b>Equipment</b>    | <b>£</b>            |
|                       |                  |                 |                  |                  | <b>£</b>            |                     |
| <i>Cost</i>           |                  |                 |                  |                  |                     |                     |
| At 1 January 2020     | 635,602          | 41,515          | 46,469           | 723,586          | 31,881              | 755,467             |
| Additions in year     | -                | -               | -                | -                | 2,990               | 2,990               |
|                       |                  |                 |                  |                  |                     |                     |
| At 31 December 2020   | <u>635,602</u>   | <u>41,515</u>   | <u>46,469</u>    | <u>723,586</u>   | <u>34,871</u>       | <u>758,457</u>      |
|                       |                  |                 |                  |                  |                     |                     |
| <i>Depreciation</i>   |                  |                 |                  |                  |                     |                     |
| At 1 January 2020     | 60,015           | 34,096          | 39,934           | 134,045          | 20,540              | 154,585             |
| Charge for year       | 12,712           | 1,855           | 1,448            | 16,015           | 2,515               | 18,530              |
|                       |                  |                 |                  |                  |                     |                     |
| At 31 December 2020   | <u>72,727</u>    | <u>35,951</u>   | <u>41,382</u>    | <u>150,060</u>   | <u>23,055</u>       | <u>173,115</u>      |
|                       |                  |                 |                  |                  |                     |                     |
| <i>Net book value</i> |                  |                 |                  |                  |                     |                     |
| At 31 December 2020   | <u>£ 562,875</u> | <u>£ 5,564</u>  | <u>£ 5,087</u>   | <u>£ 573,526</u> | <u>£ 11,816</u>     | <u>£ 585,342</u>    |
|                       |                  |                 |                  |                  |                     |                     |
| At 31 December 2019   | <u>£ 575,587</u> | <u>£ 7,419</u>  | <u>£ 6,535</u>   | <u>£ 589,541</u> | <u>£ 11,341</u>     | <u>£ 600,882</u>    |

All fixed assets are held for direct charitable purposes in Designated Funds.

# YORK AGAINST CANCER

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

### 13. DEBTORS

|                            | Charity<br>2020<br>£ | Consolidated<br>2020<br>£ | Charity<br>2019<br>£ | Consolidated<br>2019<br>£ |
|----------------------------|----------------------|---------------------------|----------------------|---------------------------|
| Amounts owed by subsidiary | 95,637               | -                         | 93,645               | -                         |
| Prepayments                | 9,250                | 13,902                    | 9,709                | 14,234                    |
| Accrued income             | 446,909              | 448,243                   | 680,096              | 680,096                   |
| Other debtors              | 140                  | 140                       | -                    | -                         |
|                            | £ 551,936            | £ 462,285                 | £ 783,450            | £ 694,330                 |

### 14. CREDITORS: amounts falling due within one year

|                              |           |           |           |           |
|------------------------------|-----------|-----------|-----------|-----------|
| Trade creditors              | 30,378    | 33,524    | 31,117    | 36,685    |
| Project creditors            | 444,038   | 444,038   | 561,184   | 561,184   |
| Taxation and social security | 3,128     | 8,730     | 3,495     | 7,582     |
| Accruals                     | 8,893     | 11,693    | 18,227    | 21,027    |
| Other creditors              | 1,122     | 1,122     | 1,148     | 1,148     |
|                              | £ 487,559 | £ 499,107 | £ 615,171 | £ 627,626 |

### 15. CREDITORS: amounts falling due after one year

|                   |           |           |             |             |
|-------------------|-----------|-----------|-------------|-------------|
| Project creditors | £ 961,016 | £ 961,016 | £ 1,252,278 | £ 1,252,278 |
|-------------------|-----------|-----------|-------------|-------------|

### 16. DESIGNATED FUNDS (consolidated)

The Charitable Company transfers to designated funds sufficient resources to meet such commitments, as shown below.

| Designated Funds - 2020 | Balance<br>01/01/2020<br>£ | Income<br>£ | Expenditure<br>£ | Transfers<br>£ | Balance<br>31/12/2020<br>£ |
|-------------------------|----------------------------|-------------|------------------|----------------|----------------------------|
| Cancer Care Centre      | 31,500                     | -           | (26,118)         | -              | 5,382                      |
| Complementary Therapy   | 35,480                     | -           | (29,116)         | -              | 6,364                      |
| Education Project       | -                          | -           | (7,170)          | 7,170          | -                          |
| Minibus                 | -                          | -           | -                | 28,000         | 28,000                     |
| Patient Travel          | -                          | -           | -                | 10,000         | 10,000                     |
| Fixed Assets Fund       | 600,882                    | -           | (18,530)         | 2,990          | 585,342                    |
| Total                   | £ 667,862                  | £ -         | £ (80,934)       | £ 48,160       | £ 635,088                  |

| Designated Funds - 2019 | Balance<br>01/01/2019<br>£ | Income<br>£ | Expenditure<br>£ | Transfers<br>£ | Balance<br>31/12/2019<br>£ |
|-------------------------|----------------------------|-------------|------------------|----------------|----------------------------|
| Cancer Care Centre      | -                          | -           | (18,900)         | 50,400         | 31,500                     |
| Complementary Therapy   | -                          | -           | (21,288)         | 56,768         | 35,480                     |
| Education Project       | -                          | -           | (26,353)         | 26,353         | -                          |
| Fixed Assets            | 609,805                    | -           | (18,849)         | 9,926          | 600,882                    |
| Total                   | £ 609,805                  | £ -         | £ (85,390)       | £ 143,447      | £ 667,862                  |

#### Cancer Care Centre

The Board is committed to a service level agreement with York Hospital to provide the funding for 3 administrator posts from 1 April 2019 to 31 March 2021.

# YORK AGAINST CANCER

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

### 16. DESIGNATED FUNDS (consolidated continued)

#### Complementary Therapy

The Board is committed to a service level agreement with York Hospital to provide the funding for a therapist post from 1 April 2019 to 31 March 2021.

#### Minibus

The trustees have set aside monies for the purchase of a new minibus which will be purchased next year.

#### Patient Travel

The trustees have set aside monies to fund Patient Travel and this will be reviewed next year once demand is known.

#### Fixed Asset Fund

This fund represents funds invested in tangible fixed assets.

#### Education Project

The Board agreed to fund the annual budgeted costs of the Education Project which is aimed at raising the awareness of cancer to the public.

### 17. RESTRICTED FUNDS (consolidated)

| Restricted Funds - 2020  | Balance<br>01/01/2020 | Income | Expenditure | Transfers | Balance<br>31/12/2020 |
|--------------------------|-----------------------|--------|-------------|-----------|-----------------------|
|                          | £                     | £      | £           | £         | £                     |
| Mobile Chemotherapy Unit | 142,069               | 600    | (321)       | -         | 142,348               |
| Prostate Cancer          | 12,222                | -      | (12,222)    | -         | -                     |
| Mouth Cancer             | 1,677                 | -      | -           | -         | 1,677                 |
| Total 2020               | £ 155,968             | £ 600  | (£ 12,543)  | £ -       | £ 144,025             |

  

| Restricted Funds - 2019  | Balance<br>01/01/2019 | Income   | Expenditure | Transfers | Balance<br>31/12/2019 |
|--------------------------|-----------------------|----------|-------------|-----------|-----------------------|
|                          | £                     | £        | £           | £         | £                     |
| Minibus Appeal           | 6,898                 | -        | (6,898)     | -         | -                     |
| Mobile Chemotherapy Unit | 139,046               | 3,023    | -           | -         | 142,069               |
| Prostate Cancer          | -                     | 12,222   | -           | -         | 12,222                |
| Mouth Cancer             | -                     | 1,677    | -           | -         | 1,677                 |
| Total 2019               | £ 145,944             | £ 16,922 | (£ 6,898)   | £ -       | £ 155,968             |

#### Minibus Appeal

The Minibus Appeal relates to funds raised for the specific purpose of purchasing and running a minibus to transport cancer patients between York Hospital and Cookridge Hospital in North Leeds.

#### Mobile Chemotherapy Unit

The Mobile Chemotherapy Unit Appeal relates to funds raised for the specific purpose of running the service.

#### Prostate Cancer

50% of the R U taking the P monies raised where to be allocated to prostate cancer research.

#### Mouth Cancer

Monies raised for the Head and Neck cancer department.

# YORK AGAINST CANCER

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

### 18. ANALYSIS OF GROUP NET ASSETS BETWEEN FUNDS

|  | General<br>Funds<br>£ | Designated<br>Funds<br>£ | Restricted<br>Funds<br>£ | Total<br>2020<br>£ |
|--|-----------------------|--------------------------|--------------------------|--------------------|
| Fund balances at 31 December 2020<br>are represented by: |                       |                          |                          |                    |
| Tangible fixed assets                                    | -                     | 585,342                  | -                        | 585,342            |
| Investments  | 3,741,010             | -                        | -                        | 3,741,010          |
| Current assets   | 1,222,644             | 49,746                   | 144,025                  | 1,416,415          |
| Current liabilities                                      | (499,107)             | -                        | -                        | (499,107)          |
| Long term liabilities                                    | (961,016)             | -                        | -                        | (961,016)          |
|  | £ 3,503,531           | £ 635,088                | £ 144,025                | £ 4,282,644        |
|  |                       |                          |                          |                    |
|  | General<br>Funds<br>£ | Designated<br>Funds<br>£ | Restricted<br>Funds<br>£ | Total<br>2019<br>£ |
| Fund balances at 31 December 2019<br>are represented by: |                       |                          |                          |                    |
| Tangible fixed assets                                    | -                     | 600,882                  | -                        | 600,882            |
| Investments  | 3,548,076             | -                        | -                        | 3,548,076          |
| Current assets   | 1,833,332             | -                        | 155,968                  | 1,989,300          |
| Current liabilities                                      | (627,626)             | -                        | -                        | (627,626)          |
| Long term liabilities                                    | (1,252,278)           | -                        | -                        | (1,252,278)        |
|  | £ 3,501,504           | £ 600,882                | £ 155,968                | £ 4,258,354        |

### 19. OPERATING LEASE COMMITMENTS

As at 31 December 2020 the charitable company had future minimum lease payments under non-cancellable operating leases as follows:

|                                | At 31 December 2020        |                          | At 31 December 2019        |                       |
|--------------------------------|----------------------------|--------------------------|----------------------------|-----------------------|
|                                | Land and<br>buildings<br>£ | Office<br>equipment<br>£ | Land and<br>buildings<br>£ | Office equipment<br>£ |
| Operating leases which expire: |                            |                          |                            |                       |
| Within one year                | 15,000                     | -                        | 15,000                     | -                     |
| Between two and five years     | -                          | -                        | 7,500                      | -                     |

### 20. RELATED PARTIES

During the year the Charitable Company paid £2,620 (2019 £2,493) to HPH Chartered Accountants for accountancy services and software costs, a firm in which the Charitable Company's Treasurer, Sarah Wearing, is a partner. At the year end there was £nil (2019 £nil) owing to HPH Chartered Accountants.

# YORK AGAINST CANCER

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

### 21. RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING ACTIVITIES

|   | 2020<br>£   | 2019<br>£ |
|---|-------------|-----------|
| Net income/(expenditure) for the reporting period   | 24,290      | (146,907) |
| Adjustments for:                                    |             |           |
| Depreciation charges                                | 18,530      | 18,849    |
| (Gains)/Losses on investments                       | (171,077)   | (351,402) |
| Dividends, interest and rents from investments      | (49,291)    | (69,033)  |
| Increase in stocks                                  | 1,964       | (14,524)  |
| Increase in debtors                                 | 232,045     | (576,507) |
| (Increase)/Decrease in creditors                    | (419,781)   | 1,145,730 |
| Net cash provided by/(used in) operating activities | £ (363,320) | £ 6,206   |

### ANALYSIS OF CASH AND CASH EQUIVALENTS

|  |                  |                    |
|--|------------------|--------------------|
| Cash at bank and in hand               | 898,835          | 1,237,711          |
| <b>Total cash and cash equivalents</b> | <b>£ 898,835</b> | <b>£ 1,237,711</b> |

### 22. VOLUNTEERS

The Charity is fortunate to be supported by over 100 volunteers. Their activities include working in our shops, attending events, supporting the office, collections and baking. Without them the Charity could not achieve what it does; their support is a massive asset in both workforce and financial terms. Whilst going about their work they are also ambassadors for the Charity which encourages more people to volunteer and support.

With varied knowledge, skills and experience the volunteers make an invaluable group. Our thanks goes to them all – together we really do make a difference to cancer patients and their families.

**YORK AGAINST CANCER**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2020**

**24. COMPARATIVE INFORMATION**

|  | Unrestricted<br>General<br>Fund<br>£ | Designated<br>Funds<br>£ | Restricted<br>Funds<br>£ | Year ended<br>31 Dec<br>2019<br>£ |
|--|--------------------------------------|--------------------------|--------------------------|-----------------------------------|
| <b>Income and endowments from:</b>                               |                                      |                          |                          |                                   |
| Donations and legacies   | 1,348,610                            | -                        | 16,922                   | 1,365,532                         |
| Other trading activities   | 274,018                              | -                        | -                        | 274,018                           |
| Investments  | 69,033                               | -                        | -                        | 69,033                            |
| <b>Total</b>   | <b>1,691,661</b>                     | <b>-</b>                 | <b>16,922</b>            | <b>1,708,583</b>                  |
| <b>Expenditure on:</b>   |                                      |                          |                          |                                   |
| Raising funds  | 186,092                              | -                        | -                        | 186,092                           |
| Charitable activities  | 1,928,512                            | 85,390                   | 6,898                    | 2,020,800                         |
| <b>Total</b>   | <b>2,114,604</b>                     | <b>85,390</b>            | <b>6,898</b>             | <b>2,206,892</b>                  |
| <b>Net income/(expenditure)<br/>before losses on investments</b> | <b>(422,943)</b>                     | <b>(85,390)</b>          | <b>10,024</b>            | <b>(498,309)</b>                  |
| Net gains/(losses) on investments                                | 351,402                              | -                        | -                        | 351,402                           |
| <b>Net income/(expenditure)</b>                                  | <b>(71,541)</b>                      | <b>(85,390)</b>          | <b>10,024</b>            | <b>(146,907)</b>                  |
| <b>Transfers between funds</b>                                   | <b>(143,447)</b>                     | <b>143,447</b>           | <b>-</b>                 | <b>-</b>                          |
| <b>Net movement in funds</b>                                     | <b>(214,988)</b>                     | <b>58,057</b>            | <b>10,024</b>            | <b>(146,907)</b>                  |
| <b>Reconciliation of funds:</b>                                  |                                      |                          |                          |                                   |
| Total funds brought forward                                      | 3,649,512                            | 609,805                  | 145,944                  | 4,405,261                         |
| <b>Total funds carried forward</b>                               | <b>£ 3,434,524</b>                   | <b>£ 667,862</b>         | <b>£ 155,968</b>         | <b>£ 4,258,354</b>                |